LLY - Why Is Eli Lilly Stock Trading Higher Premarket Tuesday? | Benzinga
Eli Lilly And Co’s (NYSE:LLY) shares are trading higher after an advisory committee to the U.S. Food and Drug Administration (FDA) delivered a favorable verdict on the company’s Alzheimer’s treatment, donanemab, declaring its benefits to surpass the associated risks.
This experimental medication targets an early stage of Alzheimer’s disease, aiming to significantly alter the treatment landscape for patients.
The panel’s unanimous endorsement now propels the treatment toward a final FDA verdict, anticipated earlier this year but delayed to allow for the expert review, reported Reuters.
Dawn Brooks, Lilly’s development leader for donanemab, expressed satisfaction with the committee’s recognition of the drug’s favorable benefit-to-risk profile. With the panel’s backing, the focus shifts to the FDA’s comprehensive review of the treatment.
The FDA’s advisers deliberated ...